Conference Reports for NATAP

20th European AIDS Conference October 15th-18th, 2025 Paris, France Back

Oral Weekly Islatravir + Lenacapavir, Efficacy, PK- Update       Oral Weekly Islatravir Plus Lenacapavir in Virologically Suppressed People with HIV-1: 96 Week Outcomes from a Phase 2 Study - (10/20/25)   Patient-Reported Outcomes From People With HIV-1 Receiving Once-Weekly Oral Islatravir in Combination With Lenacapavir: Phase 2 Week 48 Results - (10/20/25)   PK oral islatravir/LEN once weekly https://www.natap.org/2024/Glasgow/GLASGOW_09.htm   PK Missed Dose Oral Weekly Islatravir Plus Lenacapavir https://natap.org/2025/CROI/croi_06.htm   Islatravir/LEN PK Modeling of Missed Dose Scenario of Oral Weekly Islatravir Plus Lenacapavir https://natap.org/2025/CROI/croi_07.htm